drugset / Trial / NCT00652223

Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

NCT00652223 ↗

Phase 1/2 Completed 21 enrolled Cytos Biotechnology AG
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment AllQbG10 in patients with rhino-conjunctivitis and asthma due to house dust mite allergy in a single-center, open-label setting.

Timeline

Start
2005-03
Primary completion
—
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject CYT003-QbG10 Vaccine — —
Background house dust mite extract Unknown — —